Photo copyright American Heart Association, used with permission.
July 9, 2020 — Older, critically ill patients with COVID-19 (SARS-CoV-2) who received a combination of the antiretroviral medications lopinavir and ritonavir were more often seen to experience bradycardia, a slow heart rate, according to new research published today in Circulation: Arrhythmia and Electrophysiology, an American Heart Association (AHA) journal.
The combination of antiretroviral medications lopinavir (LPV) and ritonavir (RTV) have been previously used to treat patients with SARS-Cov-1 and MERS-Cov, as well for HIV-1 patients. Among HIV-1 patients, a risk of bradycardia was also reported, researchers said.
In this small, preliminary, prospective study, researchers recorded the risk of bradycardia in critically ill COVID-19 patients treated with this combination of medications. Bradycardia is classified as a heart rate below 60 beats per minute for a period of more than 24 hours. Bradycardia can cause problems if the slow heart rate leads to a decrease in blood flow to the body. This can lead to heart failure, fainting, chest pain and low blood pressure. In some people, bradycardia does not cause any symptoms.
The study included 41 patients with COVID-19 admitted to the intensive care unit at Amiens University Hospital, in Amiens, France, who were treated with 200 mg LPV and 50 mg RTV twice daily for 10 days. All patients received continuous electrocardiogram (ECG) monitoring.
Among the patients who received the LPV/RTV treatment:
• 22% experienced bradycardia for more than 24 hours.
• Bradycardia occurred at least 48 hours after initiation of treatment, indicating that the medications may have caused bradycardia.
• Blood test measuring the concentration of ritonavir (RTV plasma concentration) at 72 hours after receiving the treatment showed higher concentrations of RTV in the patients who had bradycardia.
• No correlation was found between RTV plasma concentration, LPV plasma concentration and mean heart rate at 3-days after LPV/RTV treatment began.
• Patients experiencing bradycardia were on average older than patients receiving the treatment who did not experience bradycardia (ages 62-80 vs. 54-68, respectively).
• Bradycardia resolved after LPV/RTV were discontinued or doses were reduced.
“[LPV and RTV] have complex pharmacokinetic characteristics [how the body processes a medication]... Bradycardia could be a sign of severe cardiological or neurological impairment since it is associated with lymphopenia [lower than normal number of white blood cells] that seems to reflect the severity of COVID-19 infection. Intensivists should be aware of this potential side effect in order to closely monitor LPV/RTV plasma levels, notably in elderly patients," researchers noted in the study.
Co-authors are Christophe Beyls, M.D.; Nicolas Martin, M.D.; Alexis Hermida, M.D.; Osama Abou-Arab, M.D., Ph.D.; and Yazine Mahjoub, M.D., Ph.D. Author disclosures are in the manuscript.
No funding sources were reported for this study.
Related Cardiac COVID-19 Content:
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay: A Report from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
1. Christophe Beyls, Nicolas Martin, Alexis Hermida, Osama Abou-Arab, and Yazine Mahjoub. Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. Circulation: Arrhythmia and Electrophysiology. Originally published9 Jul 2020https://doi.org/10.1161/CIRCEP.120.008798.